135934-38-2Relevant academic research and scientific papers
ENCAPSULATED RENIN INHIBITOR COMPOSITION
-
, (2008/06/13)
A pharmaceutical composition comprising a solution of a tenin inhibitor of the formula: STR1 wherein R 1 is 4-piperazinyl, 1-methyl-4-piperazinyl, 1-methyl-1-oxo-4-piperazinyl, 2-oxo-4-piperazinyl, 4-morpholinyl, 4-thiomorpholinyl or 1-methyl-4-homopiperazinyl; R 2 is benzyl, p-methoxybenzyl, 2-phenylethyl, 1-naphthylmethyl or 2-naphthylmethyl;R 3 is 4-thiazolyl, 2-amino-4-thiazolyl, 2-thiazolyl, 5-thiazolyl, 1-pyrazolyl, 3-pyrazolyl, 1-imidazolyl, n-propyl, isopropyl, CH 3 S--or CH 3 SCH 2--;R 4 is loweralkyl or cyclopropyl;R 5 is hydrogen or loweralkyl; andX is CH 2 or NH; or a pharmaceutically acceptable salt, ester or prodrug thereof in a pharmaceutically acceptable solvent, said solution being encapsulated in a soft elastic gelatin capsule.
Enzyme-catalyzed synthesis of optically pure β-sulfonamidopropionic acids. Useful starting materials for P-3 site modified renin inhibitors
Mazdiyasni, Hormoz,Konopacki, Donald B.,Dickman, Daniel A.,Zydowsky, Thomas M.
, p. 435 - 438 (2007/10/02)
The novel and efficient of several racemic β-sulfonamidopropionate esters is described. Treatment of the racemic esters with Chymotrypsin or Subtilisin Carlsberg (purified of detergent grade) provided the corresponding (S)-carboxylic acids in 60-90% yield
Psoriasis treatment
-
, (2008/06/13)
The present invention relates to the use of renin inhibitors and to renin inhibitor compositions for treatment of psoriasis.
